http://orcid.org/0000-0002-9323-2972
References
- Amrhein, V., Greenland, S., and McShane, B. (2019), “Retire Statistical Significance,” Nature, 567, 305–307. DOI: 10.1038/d41586-019-00857-9.
- Bacchetti, P. (2010), “Current Sample Size Conventions: Flaws, Harms, and Alternatives,” BMC Medicine, 8, 17. DOI: 10.1186/1741-7015-8-17.
- Bacchetti, P., McCulloch, C. E., and Segal, M. R. (2008), “Simple, Defensible Sample Sizes Based on Cost Efficiency” (with discussion), Biometrics, 64, 577–594. DOI: 10.1111/j.1541-0420.2008.01004_1.x.
- Hurlbert, S., Levine, R., and Utts, J. (2019), “Coup de Grâce for a Tough Old Bull: ‘Statistically Significant’ Expires,” The American Statistician, 73, 352–357. DOI: 10.1080/00031305.2018.1543616.
- Manski, C. (2019), “Treatment Choice With Trial Data: Statistical Decision Theory Should Supplant Hypothesis Testing,” The American Statistician, 73, 296–304. DOI: 10.1080/00031305.2018.1513377.
- Manski, C., and Tetenov, A. (2019), “Trial Size for Near Optimal Choice Between Surveillance and Aggressive Treatment: Reconsidering MSLTII,” The American Statistician, 73, 305–311. DOI: 10.1080/00031305.2018.1543617.
- McShane, B., Gal, D., Gelman, A., Robert, C., and Tackett, J. (2019), “Abandon Statistical Significance,” The American Statistician, 73, 235–245. DOI: 10.1080/00031305.2018.1527253.
- Trafimow, D. (2019), “Five Nonobvious Changes in Editorial Practice for Editors and Reviewers to Consider When Evaluating Submissions in a Post p < 0.05 Universe,” The American Statistician, 73, 340–345.
- Wasserstein, R. L., Schirm, A. L., and Lazar, N. A. (2019), “Moving to a World Beyond ‘p < 0.05’,” The American Statistician, 73, 1–19.
- Wilson, E. C. (2015), “A Practical Guide to Value of Information Analysis,” Pharmacoeconomics, 33, 105–21. DOI: 10.1007/s40273-014-0219-x.